AbbVie and Brise Pharmaceuticals have shared details on a migraine-focused deal valued at $757 million. This announcement comes two years after the two companies originally forged the partnership. The collaboration aims to advance the development of treatments for migraine, a condition that affects millions worldwide.
This deal may enhance AbbVie’s portfolio in the competitive migraine treatment market, potentially leading to new therapeutic options for patients. For manufacturers and suppliers, this partnership could signal increased investment in migraine therapies, which may influence sourcing and production strategies in the sector.
Source: pharmaceutical-technology.com · Image: Képhaldol by Unknown authorUnknown author, Public domain, via Wikimedia Commons
Open the full market picture for your next decision →
